Pfizer joins PD-1xVEGF race with $1.25B upfront to Chinese biotech 3SBio
Pfizer is set to enter the heated VEGF bispecific arena. The New York drug giant is doing so by going to China, much like its peers Summit Therapeutics,
Pfizer is set to enter the heated VEGF bispecific arena.
The New York drug giant is doing so by going to China, much like its peers Summit Therapeutics,
